[Evaluation of SM-4300, a new intact gammaglobulin, with venoglobulin-I].
Evaluation of SM-4300, a new intact gammaglobulin for peritoneal use, about antimicrobial titers and prophylactic effects on bacterial infections in mice was performed. The results are as follows: The antimicrobial titers of SM-4300 against bacteria, protozoa, and virus were almost the same as those of venoglobulin-I, another intact gammaglobulin. The difference in antimicrobial titers among several lots of SM-4300 was unrecognizable. Prophylactic effects of SM-4300 on systemic infections in granulocytopenic mice were remarkable and were comparable to those of venoglobulin-I. About 9% of venoglobulin-I treated mice died within 24 hours after the injection. On the contrary, no mice died by SM-4300 treatment.
M
M
Kato
K
K
Kadota
T
T
Okuda
D000380:Agranulocytosis / Q000150:complications; D000818:Animals; D001424:Bacterial Infections / Q000517:prevention & control*; D004338:Drug Combinations / Q000494:pharmacology / Q000627:therapeutic use; D056890:Eukaryota / Q000276:immunology; D005341:Fibrinolysin / Q000494:pharmacology* / Q000627:therapeutic use; D006090:Gram-Negative Bacteria / Q000276:immunology; D006094:Gram-Positive Bacteria / Q000276:immunology; D007116:Immunization, Passive; D007136:Immunoglobulins / Q000494:pharmacology*; D016756:Immunoglobulins, Intravenous; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D014780:Viruses / Q000276:immunology; D005719:gamma-Globulins / Q000494:pharmacology* / Q000627:therapeutic use
D004338:Drug Combinations; D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; C044640:SM-4300; D005719:gamma-Globulins; D005341:Fibrinolysin